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NCL proteinsThe fatal, primarily childhood neurodegenerative disorders, neuronal ceroid lipofuscinoses (NCLs), are currently
associated with mutations in 13 genes. The protein products of these genes (CLN1 to CLN14) differ in their func-
tion and their intracellular localization. NCL-associated proteins have been localized mostly in lysosomes (CLN1,
CLN2, CLN3, CLN5, CLN7, CLN10, CLN12 and CLN13) but also in the Endoplasmic Reticulum (CLN6 and CLN8), or
in the cytosol associated to vesicularmembranes (CLN4 and CLN14). Some of them such as CLN1 (palmitoyl pro-
tein thioesterase 1), CLN2 (tripeptidyl-peptidase 1), CLN5, CLN10 (cathepsin D), and CLN13 (cathepsin F), are ly-
sosomal soluble proteins; others like CLN3, CLN7, and CLN12, have been proposed to be lysosomal
transmembrane proteins. In this review, we give our views and attempt to summarize the proposed and con-
ﬁrmed functions of each NCL protein and describe and discuss research results published since the last review
on NCL proteins. This article is part of a Special Issue entitled: "Current Research on the Neuronal Ceroid
Lipofuscinoses (Batten Disease)”.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease,
make up themost commongroup of inherited neurodegenerative disor-
ders of childhood, with selective destruction and loss of neurons in the
cerebral, cerebellar cortex and retina. Most NCLs show an autosomal re-
cessive mode of inheritance, and are classiﬁed according to the severity
of the resulting mutations and the ages of onset such as congenital, in-
fantile, late infantile, juvenile, adult or even late adult onset. They
share clinical features such as progressive loss of vision aswell asmental
and motor deterioration, epileptic seizures, and eventually premature
death.
NCLs are considered lysosomal storage diseases (LSD) characterized
by a heterogeneous origin of the storage material. This material consists
mostly of accumulation of ceroid-lipopigments, subunit c ofmitochondri-
al ATP synthase or sphingolipid activator proteins A and D in lysosomes.
Commonly, the accumulated ceroid-lipopigments are autoﬂuorescent
and are positive for periodic acid–Schiff (PAS), which stains polysaccha-
rides, glycoproteins and glycolipids, Luxol fast blue (LFB), which stains
lipoproteins in themyelin sheath, Sudan black B, which stains neutral tri-
glycerides and lipoproteins, and the Ziehl-Neelsen acid fast stain, which
stains mycolic acids [1]. The nature of the storage material accumulation
in NCLs might be a result of an ancillary process and may not necessarilyesearch on theNeuronal Ceroid
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Pearce).lead to clarifying the functions of NCL-causing gene products. Neverthe-
less, the elucidationof thenature and cell location of the involvedproteins
underlying such common clinical and pathological features is crucial to
disentangle the affected pathways and to ascertain common processes.
NCL-associated proteins (CLN1 to CLN14) differ in their function and
their intracellular localization (see Table 1). NCL proteins have been lo-
calized mostly in lysosomes (CLN1, CLN2, CLN3, CLN5, CLN7, CLN10,
CLN12 and CLN13) but also in the Endoplasmic Reticulum (ER) (CLN6
and CLN8), or in the cytosol associated to vesicular membranes (CLN4
and CLN14). Some of them such as CLN1, which is palmitoyl protein
thioesterase 1 (PPT1), CLN2, which is tripeptidyl-peptidase 1 (TPP1),
CLN5 with unknown function, CLN10, which is cathepsin D, and
CLN13, which is cathepsin F, are lysosomal soluble proteins; some
other like CLN3, CLN7, and CLN12, have been proposed to be lysosomal
transmembrane proteins.
Mutations in theseNCLproteins cause the different forms of NCL dis-
ease and the potential interactions between proteins affecting different
NCLpathways have been studied. In this review,we summarize the pro-
posed and conﬁrmed functions of each NCL protein and describe and
discuss research results published since the last review on NCL proteins
[2]. Despite the research efforts, a deﬁnitive function has not been
established for the majority of NCL proteins.
2. NCL proteins
2.1. CLN1 (palmitoyl protein thioesterase 1)
Mutations of the CLN1 gene cause infantile CLN1 disease, which is
the most severe form of NCLs, presents in children at 1–2 years of age,
Table 1
NCL proteins and their subcellular localization and function.
NCL gene Protein Subcellular localization Function
CLN1 CLN1/Palmitoyl protein thioesterase 1
(PPT1)
306 aa, soluble protein
Lysosomal matrix, extralysosomal vesicles, lipid
rafts, ER and presynaptic areas in neurons
Palmitoyl thioesterase; associated to
endo/exocytosis in synaptic vesicle recycling, to
cholesterol metabolism and to apoptosis
CLN2 CLN2/Tripeptidyl-peptidase 1 (TPP1)
563 aa, soluble protein
Lysosomal matrix and ER Serine protease; associated to macroautophagy,
endocytosis and TNF-α-induced apoptosis
CLN3 CLN3
438 aa, transmembrane protein,
(6 transmembrane domains)
Late endosomal/lysosomal membrane Unknown function; postulated to have a role in
endocytosis, autophagy, maintenance of
vacuolar/lysosomal pH, anterograde/retrograde
transport of lysosomal enzyme transporters,
osmoregulation, apoptosis and cell cycle control
CLN4 CLN4/Cysteine-string protein alpha
(CSPα)/DNAJC5
198 aa, soluble protein
Cytosolic, associated to vesicular membranes, to
synaptic vesicles in neurons, and to secretory
granules in endo/exo/neurocrine cells
Hsc70 co-chaperone; involved in presynaptic
endo/exocytosis; function is fully rescued by
α-synuclein
CLN5 CLN5
407 aa, soluble protein
Lysosomal matrix Unknown function; involved in sphingolipid
transport and synthesis, myelination, cell, growth,
apoptosis, and retrograde transport of the
lysosomal enzyme transporter, CIMPR
CLN6 CLN6
311 aa, transmembrane protein
(7 transmembrane domains)
ER membrane Unknown function; associated to autophagy,
endocytosis, regulation of pH and biometal
metabolism
CLN7 CLN7/MFSD8
518 aa, transmembrane protein
(12 transmembrane domains)
Lysosomal membrane Unknown function; predicted to have a role in the
transport of small substrates across cellular
membranes
CLN8 CLN8
286 aa, transmembrane protein
(5 transmembrane domains)
ER/ ER-Golgi intermediate compartment
membrane
Unknown function; postulated to have a central
role in the regulation of sphingolipid transport and
synthesis; also related to oxidative and ER stresses,
mitochondrial function, calcium homeostasis,
inﬂammation and apoptosis
CLN9 CLN9
Unknown protein
Unknown localization Unknown function
CLN10 CLN10/Cathepsin D (CTSD)
412 aa, soluble protein
Lysosomal matrix and extracellular Aspartyl endopeptidase; have major roles in
apoptosis and autophagy; in cancer cells has major
roles in proliferation, angiogenesis, invasion and
metastasis
CLN 11 CLN11/Progranulin/
Proepithelin/Acrogranin
593 aa, soluble protein
Extracellular Unknown function; main role associated to
autophagy but also reported roles in inﬂammation,
embryogenesis, cell motility and tumorigenesis
CLN 12 CLN12/ATPase
13A2/KRPPD/PARK9/HSA9947/ RP-37C10.4
1180 aa, transmembrane protein
(10 transmembrane domains)
Lysosomal membrane and multivesicular
bodies.
Unknown function; predicted to shuttle cations,
heavy metals and lipids across cell membranes;
also postulated to be involved in pH homeostasis,
lysosomal degradation, biometal homeostasis, and
protection against α-synuclein toxicity
CLN 13 CLN13/Cathepsin F
484 aa, soluble protein
Lysosomal matrix Cysteine protease; has been mainly associated to
proteasome degradation and autophagy; also
related to cell immunity and lipoprotein
degradation
CLN 14 CLN14/Potassium channel tetramerization
domain-containing protein 7 (KCTD7)
289 aa, soluble protein
Cytosolic and also partially associated to the
plasma membrane
Unknown function; predicted to be involved in the
hyperpolarization of the neuronal cell membrane;
also associated to proteasome degradation
aa: amino acid.
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milder disease forms including late infantile, juvenile, or adult pheno-
type have also been reported [4,5]. The CLN1 gene encodes palmitoyl
protein thioesterase 1 (PPT1), a soluble lysosomal enzyme involved in
lysosomal degradation of S-fatty acylated proteins [6–8]. Low or inexis-
tent levels of palmitoyl protein thioesterase 1 (PPT1) and granular
osmiophilic deposits (GRODs) in leukocytes are the distinctive hall-
marks of infantile CLN1 disease.
The crystal structure of PPT1 revealed a soluble, globular monomer
with an α/β hydrolase fold and a catalytic triad (S115, D233, H289)
[8]. Ohno et al. postulated that there is a structural basis for the effect
of PPT1 mutants showing that mutations which exhibited a total loss
of enzymatic activity affected the core region of the enzyme [9]. Despite
not knowing precisely neither the in vivo substrates of PPT1-mediated
depalmitoylation activity nor its precise physiological role, several
reports have shown the association of PPT1 to the F1 complex of
mitochondrial ATP synthase, H-Ras, palmitoyl-CoA, α subunits of
heterotrimeric G proteins or neuron-speciﬁc GAP43 and rhodopsin
[10–13]. Experiments showing depalmitoylation of GAP-43 and rho-
dopsin peptides by PPT1 in vitro demonstrated that the enzyme wasmore efﬁcient at neutral pH (7.4) than at acidic pH (4.0) [13]. This
could be considered as potential evidence for a possible extralysosomal
function of PPT1. Besides lysosomes PPT1 has also been found in lipid
rafts with a suggested role in regulating lipid content in CHO cells as
overexpression of PPT1 resulted in decreased ceramide contents rela-
tive to cholesterol and sphingomyelin [14]. In neurons, the localization
and functional activity of PPT1 is not limited to lysosomes, PPT1 is also
found in the presynaptic area [15–17], suggesting a neuron-speciﬁc
function of PPT1. Supporting this notion, the expression of PPT1 in
human and mouse brain is developmentally regulated and coincides
with cortical synaptogenesis [18–20].
Studies inDrosophilahave indicated that PPT1 is involved in endocy-
tosis. In Ppt1 loss-of-function Drosophilamutants, Garland cells, a small
groupof nephrocytes that take upwastematerials from the hemolymph
by endocytosis, had defects in endocytic trafﬁcking [21]. Endocytic trac-
er uptake and ultrastructural analysis of these Garland cells indicated
that PPT1plays a role inmodulating the early stages of vesicle formation
[21]. A recent study by Aby et al. examined the consequences of Ppt1
mutations at the Drosophila larval neuromuscular junction, a very
well-characterized synapse. They showed changes in synaptic vesicle
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recover from repetitive stimulation and by reductions in FM1-43uptake
in the Ppt1-mutant larval nerve terminals [22]. The authors’ ﬁndings
highlight the importance of PPT1 and palmitoylation in general, in
synaptic vesicle exo- and endocytosis and neuromuscular function
[22]. A previous study by Kim et al. using postmortem brain tissues
from a patient with infantile CLN1 disease and tissue from Ppt1-knockout
(Ppt1-/-) mice that mimic infantile CLN1 disease, had corroborated the
Drosophila studies [23]. Neuronal communication relies on repeated cycles
of exo- and endocytosis of the neurotransmitter-laden synaptic ves-
icles (SVs) at the nerve terminals [24–27], and Kim et al. reported
that PPT1 deﬁciency causes persistent membrane anchorage of the
palmitoylated SV proteins VAMP2 and SNAP25, impairing, subse-
quently, the regeneration of fresh SVs, an essential process for main-
taining the SV pool size at the synapses [23].
In most NCL diseases the storage material consists mainly of subunit c
of ATP synthase,while in infantile CLN1 and congenital CLN10diseases the
main components of storage material are sphingolipid activator proteins
(SAPs) A and D [28,29]. Examining the possible implications of PPT1 in
lipid accumulation Lyly et al. showed that in PPT1-deﬁcient mouse prima-
ry neurons, there is an increased amount of subunits of the F1 complex of
mitochondrial ATP-synthase in the plasma membrane and increased up-
take of apolipoprotein A (apoA-1) by this complex, therefore postulating
a role for PPT1 in cholesterol metabolism [10].
Recent therapeutic approaches also provided some insights into the
function of PPT1. Treatment of Ppt1-/- mice with a non-toxic hydroxyl-
amine derivative, N-(tert-Butyl) hydroxylamine (NtBuHA) known to
cleave thioester linkage in palmitoylated proteins depleted lysosomal
ceroid, suppressed neuronal apoptosis, slowed neurological deteriora-
tion and extended lifespan [30]. In cultured ﬁbroblasts and lympho-
blasts from infantile CLN1 disease patients with nonsense CLN1
mutations, PTC124, a read-through drug that promotes translation
through premature stop codons, increased PPT1 enzyme activity [31,
32] and slightly affected apoptosis [31]. Kim et al. reported that neuro-
nal apoptosis in infantile CLN1 disease is caused by caspase-4 activation
leading to caspase-3 effector activation, and that inhibition of caspase-4
activity is cytoprotective in lymphoblasts from infantile CLN1 disease
patients [33]. They conﬁrmed that the PPT1-targeted protein, GAP43 is
accumulated in the ER in the affected lymphoblasts and suggested
that ER stress-induced activation of the unfolded protein response
(UPR) mediates caspase-4 and caspase-3 activation, and apoptosis
[33]. Finally, the same group reported that the use of antioxidant
drugs such as omega-3 and omega-6 fatty acids [34] and resveratrol
[35], reduces oxidative stress and suppresses apoptosis in Ppt1-/- mice,
resulting in a very modest increase in life span [35].
Apotential link betweenPPT1 and another soluble lysosomalNCLpro-
tein, CLN5 has also been found: GST-CLN5 pulled down endogenous PPT1
from both mouse brain extract and HeLa cell lysates, and overexpressed
PPT1 and CLN5 colocalized in cultured cells as shown by confocal micros-
copy [36]. In the same study, when CLN5with the most common Finnish
variant late infantile NCL-causing mutation (p.Y392X) was expressed in
HeLa cells and in neuroblastoma cells (SH-SY5Y), the mutant CLN5
was retained in the ER and did not colocalize with the lysosomal
marker LAMP-1. Interestingly, simultaneous overexpression of wild
type PPT1 with mutated CLN5 in both cell lines resulted in co-
localization of the two proteins in LAMP-1 positive lysosomes [36].
All in all, the synapse-speciﬁc role of PPT1, regulating synaptic vesicle
exo- and endocytosis [22,23] and thus, neurotransmission and synaptic
integrity, is the most likely explanation for the rapid neurodegeneration
occurring in infantile CLN1 disease. Further studies are required to clarify
how exactly PPT1 deﬁciency leads to neuronal death.
2.2. CLN2 (tripeptidyl-peptidase 1)
Mutations in CLN2, which encodes tripeptidyl-peptidase 1 (TPP1),
cause late infantile CLN2 disease, which presents in children at 2–4years of age, and typically leads to death by 6–15 years of age [37].
TPP1 has also been identiﬁed as the causative gene for autosomal reces-
sive spinocerebellar ataxia 7 (SCAR7) by exome sequencing. [38]. TPP1
is a serine protease that is active at an acidic pH optimum to remove
tripeptides from the amino terminus of proteins but its in vivo sub-
strates are unknown. TPP1 is synthesized as an inactive proenzyme
(pro-TPP1) that is proteolytically processed into the active enzyme
after exposure to low pH in vitro or targeting to the lysosome in vivo
[39]. Transfection experiments have indicated that TPP1 mutants have
delayed processing and are retained in the ER rather than transported
to lysosomes [40]. The same studies also showed that Ca2+ is necessary
for the autocatalytic processing of the precursor protein into themature
TPP1 [40]. Several studies have conﬁrmed that the CLN2/Cln2 gene is
ubiquitously expressed in human, rat and mouse tissues and it is devel-
opmentally regulated [41–44]. Koike et al. measured TPP1 (CLN2) pro-
tein levels in various tissues from adult rats and mice and found that
TPP1 was highly expressed in the brain [41]. Another study in human
subjects showed that the expression of TPP1 in the cerebral cortex
increased with development, and reached adult levels after the age of
2 [42].
Although the knowledge of the in vivo interacting partners of TTP1
could give us key information regarding its function, the native sub-
strates of TPP1 and its exact physiological roles are not known. Never-
theless, several studies in vitro have described distinct interactions of
TPP1 with different substrates [45–48]. Peptide hormones such as
angiotensin II [45], glucagon [46], substance P [45], cholecystokinin
and neuromedin [46,47], as well as synthetic amyloid-β-peptides and
the mitochondrial ATP synthase subunit c [48], were cleaved by TPP1
in vitro.
Late infantile CLN2 disease has been lately associated with
macroautophagy and with defective endosomal/lysosomal cell process-
es [49,50]. Micsenyi et al. described signiﬁcantly increased levels of mi-
crotubule‐associated protein 1 light chain 3 (LC3-II), an autophagy
marker, in cerebrum and cerebellum extracts in 13-week-old TPP1-
deﬁcientmice, consistentwith defectivemacroautophagosomematura-
tion in the last stages of the disease [49]. Vidal-Donet et al. showed up-
regulated Akt-mTOR signaling pathway in late infantile CLN2 disease
ﬁbroblasts and a reduced formation of autophagosomes. This study
also indicated that the observed accumulation of higher amounts of
Radical Oxygen Species (ROS) in late infantile CLN2 disease ﬁbroblasts
and a decrease in catalase activity could both increase the accumulation
rate of peroxidized lipids and lipofuscin in late infantile CLN2 disease
[50].
Generation of induced pluripotent stem cells (iPSCs) from patient’s
ﬁbroblasts and subsequent differentiation of the iPSCs to speciﬁc cell
types of interest has become a powerful tool for human disease model-
ing and therapeutic screening [51,52]. Lojewski et al. generated iPSCs
from late infantile CLN2 disease and juvenile CLN3 disease patients’
ﬁbroblasts and also generated neural progenitor cell lines (NPC) from
the iPSCs [52]. Despite the reported changes inmacroautophagy andde-
fective endosomal/lysosomal cell processes found in late infantile CLN2
disease ﬁbroblasts [50] Lojewski et al. found no changes in the area of
the autophagic degradative vacuoles in late infantile CLN2 disease
iPSCs [52]. When TPP1 expression was measured in juvenile CLN3 dis-
ease iPSCs andneural progenitor cells, interesting resultswere obtained.
TPP1 expression in the iPSCs derived from juvenile CLN3 disease pa-
tients was signiﬁcantly lower than in non-affected, control iPSCs,
whereas in neural progenitor cells derived from juvenile CLN3 disease
iPSCs, TPP1 expression was signiﬁcantly higher than those derived
from non-affected, control iPSCs [52]. This might be due to a cell-type
speciﬁc compensatory response to the CLN3 deﬁciency. Previous studies
have also shown increased TPP1 activity in the brain of Cln3-/-mice and
juvenile CLN3 disease patients [53–55].
TPP1 has also been proposed to play a central role in TNFα-induced
apoptosis [56]. According to this study, ﬁbroblasts from late infantile
CLN2 disease patients are resistant to TNFα-induced apoptosis and
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Nevertheless, a month later, a paper by Kim et al. showed that in the
Tpp1-/- mouse model of late infantile CLN2 disease, genetic modulation
of p53 or Bcl-2 expression did not affect neurodegeneration, tremor
onset or frequency, and the characteristic shortened life-span [57]. The
authors also suggested that neuronal death in late infantile CLN2disease
either does not occur via apoptosis or it occurs via apoptotic pathways
not involving p53 or Bcl-2 [57].
In conclusion, the involvement of TPP1 in macroautophagy and
TNFα-induced apoptosis indicates that this lysosomal serine protease
affects cell viability. It is still unknown, however, how TPP1-deﬁciency
causes selective neurodegeneration.
2.3. CLN3
Recessive mutations in the CLN3 gene cause juvenile CLN3 disease,
the most common subtype of NCLs [58]. Although, CLN3 mutations
primarily affect neurological processes causing vision loss, seizures,
and progressive motor and cognitive decline, there is also evidence of
pathology outside of the central nervous system, more speciﬁcally in
the cardiac and immune systems [59–62]. CLN3 encodes a 438-amino
acid putative lysosomal transmembrane proteinwith 6 transmembrane
domains, with both N- and C-termini in the cytosol [63,64]. The most
frequent disease-causing mutation of the CLN3 gene is a 1 kb deletion,
which removes exons 7 and 8 and creates a premature stop codon.
This mutation results in a substantial decrease in mRNA expression
and stability, so most likely the mutant, truncated protein is not
expressed at all [65]. Expression analyses indicate that the CLN3/Cln3
gene and CLN3 protein is ubiquitously expressed in various human
andmouse tissues [58,66–69]. Tissue expression pattern and intracellu-
lar localization of CLN3 has not been completely elucidated mainly be-
cause of low endogenous CLN3 levels and the lack of suitable, speciﬁc
antibodies. The precise cellular function of CLN3 is not completely
known. CLN3 has been primarily found in endosomes and lysosomes
with a suggested involvement in endocytosis and endocytic trafﬁcking
[50,70–74]. The yeast ortholog of CLN3, Btn1p, has been shown to play
an important role in the transport of a subset of proteins between the
vacuole (the yeast equivalent of the lysosome) and the trans-Golgi
network [75,76]. Using small interfering RNA (siRNA)-mediated abla-
tion of CLN3 in HeLa cells expressing the Cation-Independent Mannose
6-Phosphate Receptor (CI-MPR) reporter, itwas found that CLN3 plays a
key role in the exit of CI-MPR (CD8-CI-MPR) from the trans-Golgi net-
work [77]. CLN3 has also been linked to autophagy [78]. Vidal-Donet
et al. have reported a clear impairment of macroautophagy maturation
in juvenile CLN3 disease patients’ ﬁbroblasts alongside a 0.6 increase in
lysosomal pH in these ﬁbroblasts, which could be a causal or contribu-
tive factor of altered macroautophagy [50]. Lojewski et al. also observed
abnormalities of autophagy in juvenile CLN3 disease patient-derived iPS
cells and in neural progenitor cells derived from juvenile CLN3 disease
iPSCs [52]. Although the average number of autophagic vacuoles per
cell (normalized to total cell area) did not differ signiﬁcantly in compar-
isonwith the control cell line, the average area of the identiﬁed autoph-
agic vacuoles in juvenile CLN3 disease patient-derived iPS cells was
signiﬁcantly larger than in control cells as observed by transmission
electronmicroscopy. In juvenile CLN3 disease iPSCs-derived neural pro-
genitor cells, ultrastructural analysis revealed a signiﬁcantly higher
number of empty vacuoles and a marked depletion of multivesicular
bodies [52]. The observed abnormalities could be the result of defective
fusion events such as those previously observed in cerebrum and cere-
bellum extracts [49]. Other studies in yeast lacking Btn1p, the ortholog
protein of CLN3, as well as subsequent analyses in patients’ ﬁbroblasts
and human embryonic kidney cellswithmutated CLN3 have showndis-
turbances in themaintenance of the vacuolar/lysosomal pH [50,79–81].
A recent study using Amoeba Dictyostelium localized CLN3 fused to
GFP in the contractile vacuole system that acts as an osmoregulatory or-
ganelle and controls the intracellular water balance by collecting andexpelling excess water out of the cell [82]. In spite of the lack of
kidney-related clinical symptoms in juvenile CLN3 disease patients,
ﬁndings by Stein et al. suggest an osmoregulated role for CLN3 in
renal control of water and K+ balance. This group used a Cln3 reporter
mouse harboring a nuclear-localized bacterial β-galactosidase (β-Gal)
gene driven by the native Cln3 promoter and detected β-Gal most
prominently in epithelial cells of skin, colon, lung, and kidney [83]. In
the kidney, β-Gal-positive nuclei were predominant in medullary
collecting duct principal cells, with increased expression along themed-
ullary osmotic gradient, and reporter mouse-derived renal epithelial
cultures demonstrated an increase in β-Gal expression that was depen-
dent on tonicity [83]. Following this report, Getty et al. tested if human
CLN3 expression and localization is affected by osmotic changes in a sta-
bly transfected BHK (baby hamster kidney) cell line that expresses a
moderate level of myc-tagged human CLN3 under the control of the
human ubiquitin C promoter [84]. Hyperosmolarity (800 mOsm),
achieved by either NaCl/urea or sucrose, dramatically increased the
mRNA and protein levels of CLN3 as determined by quantitative
real-time PCR and Western blotting. The subcellular localization of
myc-tagged CLN3 also changed dramatically: under isotonic condi-
tions (300 mOsm), human CLN3 was found in a punctate vesicular
pattern surrounding the nucleus with prominent Golgi and lysosom-
al localizations, and hyperosmolarity (800 mOsm) extended CLN3
distribution away from the perinuclear region and enhanced its lyso-
somal localization [84].
CLN3 has also been associated with cell migration, cell morphology,
and myosin distribution [85,86]. Getty et al. reported an interaction be-
tweenmyosin IIB and CLN3, and suggested that the observedmigration
defect in Cln3-/- mouse embryonic ﬁbroblasts results, in part, from the
loss of the CLN3-myosin-IIB interaction [85].
Besides the attributed roles in lysosomes, CLN3 has been widely as-
sociated with cell proliferation, apoptosis and control of cell cycle. A re-
cent study reported increased rates of proliferation in Cln3-/- Amoeba
Dictyostelium [82]. Cell cycle arrest has been detected in the G1/G0
phase in CLN3-silenced colorectal cancer cells [87] and in lymphoblast
cells from juvenile CLN3 disease patients [88]. The later study also indi-
cated an accumulation of p21, sphingosine, glucosylceramide, and
sulfatide as possible cell cycle regulators [88]. Overexpressed p21
might be involved in cell cycle arrest and induction of apoptosis but the
group showed very scarcely apoptosis-indicating results [88]. The same
group also reported enhanced levels of gangliosides and α-synuclein
oligomers, and reduced levels of sphingomyelin and autophagy in juve-
nile CLN3disease lymphoblast cells [89], providing a possible explanation
for the higher rate of cell death typically found in juvenile CLN3 disease
lymphoblast cells. Rusyn et al. reported that wild type CLN3, but not mu-
tant CLN3, binds galactosylceramide, and suggested that wild type CLN3
may function as a galactosylceramide transporter [90]. The same study
also indicated that inhibition of galactosylceramide synthesis in normal
cells by galactosylceramide synthase siRNA negatively affects cell growth
and induces apoptosis, suggesting that galactosylceramide could be a
center piece in the reported alterations in cell growth or apoptosis in
juvenile CLN3 disease cells [90]. Apoptosis speciﬁcally, however, was
not measured by Rusyn et al. [90]: to detect apoptosis they used
propidium iodide uptake, which detects cells dying by necrosis (primary
necrosis or secondary necrosis ~24-48 h after apoptosis). Zhu et al. also
reported that silencing of CLN3 by siRNA in HCT116 colorectal cancer
cells inhibited proliferation, promoted apoptosis and induced G0/G1 cell
cycle arrest [87]. Wu et al. showed that CLN3 overexpression increased
the proliferation and conferred resistance to tunicamycin induced
apoptosis in neuroblastoma SH-SY5Y cells [91].
All in all, CLN3 affects a number of cellular processes including
lysosmal pH regulation, autophagy, endocytosis, protein transport
from the trans-Golgi, proliferation and apoptosis. It is unclear, however,
in which process CLN3 plays a real functional role and which process is
affected as a secondary consequence of its primary function. As regards
the selective neurodegeneration in juvenile CLN3 disease, loss of any of
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stance, the endocytic defect caused by CLN3mutations can change neu-
rotransmitter release and surface expression of receptors and ion
channels in neurons, leading to impaired neurotransmission and even-
tually neuronal cell death. A few studies in mouse models of juvenile
CLN3 disease provide supporting evidence for this scenario [92–94].
2.4. CLN4 (Cysteine-string protein α)
Mutations in the CLN4 gene cause some adult onset forms of NCL
under the name of Kufs disease. Kufs disease is the least frequent
amongNCL types and themost difﬁcult to diagnose [95,96]. Two clinical
variants of Kufs disease exist: type A, characterized by progressive my-
oclonus epilepsy and cognitive decline, and type B, characterized by
movement and behavioral abnormalities and dementia [97].
Identifying the molecular basis of the dominant form of adult NCL,
Kufs Disease type A, it turned out that CLN4 is theDNAJC5 gene encoding
cysteine-string proteinα (CSPα), [98,99]. CSPα is a chaperone to ensure
protein folding and it has been found on synaptic vesicles in neurons ac-
counting for 1% of total vesicle proteins [100], and also on secretory gran-
ules in various endocrine, neurocrine and exocrine cells [101]. The
disease-causing mutations occur within the highly conserved cysteine-
string region that is responsible for membrane binding/targeting and
oligomerization [98]. A recent study in Caenorhabditis elegans showed
that mutating dnj-14, the ortholog of DNAJC5, results in shortened
lifespan and a small impairment of locomotion and neurotransmission.
Worms with mutant dnj-14 also presented age-dependent neurodegen-
eration of sensory neurons [102].
Several studies have conﬁrmed that the lack of CSPα in mice pro-
duces progressive defects in neurotransmission, synapse loss, neurode-
generation, and early lethality, whereas themoderate overexpression of
wild-type α-synuclein, a small presynaptic protein linked to Parkinson
disease, fully rescues the CSPα-null phenotype [103,104]. In spite of
the lack of interaction between the two proteins [103], these studies
suggest that α-synuclein is in the same biochemical pathway as CSPα
[103,104]. It has been shown that CSPα forms a chaperone complex
with Hsc70 (heat shock cognate protein of 70 kDa) and SGT (Small
Glutamine-rich Tetratricopeptide repeat-containing protein) on synap-
tic vesicles and does not participate directly in exocytosis by binding
calcium channels [105–107]. Research by Garcia-Junco-Clemente et al.
using primary hippocampal neurons from CSPα-deﬁcient mice indi-
cates that CSPα may regulate the synaptic vesicle cycle through
refolding or switching the conformation of proteins necessary for the
cycle and that with repeated ﬁring and multiple rounds of the synaptic
vesicle cycle, CSPα-deﬁcient synapses likely accumulate incorrect con-
formations of CSPα-interacting proteins, eventually leading to synaptic
dysfunction and loss [108].
In order to clarify what are the actual interacting partners of CSPα,
Zhang et al. screened over 1500 unique synaptic proteins and found
that the levels of 22 proteins were selectively decreased in CSPα-
deﬁcient synapses [109]. Two of these putative CSPα interacting part-
ners, SNAP-25 (synaptosomal-associated protein, 25 kDa) and the
GTPase dynamin 1, which are necessary for synaptic vesicle fusion and
ﬁssion, respectively, directly bound to the CSPα-Hsc70-SGT chaperone
complex [109]. Sharma et al. also found that the CSPα-Hsc70-SGT com-
plex binds directly to monomeric SNAP-25 to prevent its aggregation
enabling it to function in synaptic vesicle exocytosis [110]. A recent
study by Chiang et al. indicates that in PC12 cells CSPα regulates the
exocytosis of synaptic vesicle-like microvesicles by modulating fusion
pore dynamics in a phosphorylation-dependent (at Ser10 of CSPα)
manner [111].
In conclusion, CSPα plays an important role in synaptic vesicle exo-
and endocytosis, maintaining normal neurotransmission and synaptic
stability, and thereby, overall neuronal viability. Neurodegeneration in
CSPα-deﬁcient mice is primarily produced by defective SNAP-25 func-
tion, which impairs SNARE (Soluble N-ethylmaleimide sensitive factorAttachment protein REceptors) complex assembly and prevents synap-
tic vesicle exocytosis [112].
2.5. CLN5
Defects in the CLN5 gene were originally identiﬁed as causing a so-
called Finnish variant of late infantile NCL. Nevertheless, nowadays,
this variant has also been described in NCL patients of broad ethnicity,
and early juvenile and adult cases caused by CLN5 mutations have
recently been reported [113–115].
CLN5/Cln5 mRNA has been detected mostly in human and mouse
brain but also in peripheral organs [116,117]. Cln5mRNA expression is
particularly high in the cerebral cortex, cerebellum, and in the ganglion-
ic eminence of the embryonic mouse brain. In the postnatal mouse
brain, expression of the CLN5 protein is prominent in cerebellar
Purkinje cells, cortical neurons, hippocampal pyramidal neurons, and
hypothalamic neurons [117]. Recently, Schmiedt et al. reported that
the Cln5 gene in mice is developmentally regulated, and its highest ex-
pression in microglial cells within the brain and a very early activation
of microglia in Cln5-knockout (Cln5-/-) mice suggest a role for CLN5 in
regulating microglial function [118].
Human CLN5 consists of 407 amino acids with an N-terminal signal
sequence that is cleaved after entering the Endoplasmic Reticulum. An-
other major modiﬁcation in CLN5 is N-glycosylation. It has been shown
that there are eight putative N-glycosylation sites of human CLN5 that
are utilized in vivo and that mutations in these sites could affect folding,
trafﬁcking or lysosomal function [119]. CLN5 is a soluble protein that
localizes to the lysosomal compartment [120,121]. Its localization has
been conﬁrmed by several colocalization studies using anti-lysosome-
associated membrane protein 1 (LAMP1) antibodies in cells overex-
pressing CLN5 [36,117,122,123]. CLN5 has been suggested to interact
with other NCL proteins in COS-1 cells overexpressing PPT1, CLN3,
CLN6 and CLN8 and in the same cells with endogenously expressed
TPP1 [36,122].
In Cln5-/- mice, alterations in serum lipid proﬁles, defective lipid
transport and hypomyelination were found, indicating the involvement
of CLN5 in lipidmetabolism [118]. CLN5 has also been suggested to func-
tion as a modulator of dihydroceramide synthase (CerS) and also of cell
growth and apoptosis [124,125]. It was found that sphingolipids down-
streamof CerS, namely ceramide anddihydroceramidewere diminished
in ﬁbroblasts from CLN5-deﬁcient patients [125], ﬁrst described as CLN9
variant [124]. Haddad et al. hypothesized that CLN5 and CLN8 are func-
tionally related as CLN8 corrects CLN5 defects and altogether modulate
dihydroceramide synthase 1 and 2 [125]. Nevertheless, they did
not prove that both CLN5 and CerS or both CLN5 and CLN8
coimmunoprecipitated in either the normal ﬁbroblasts or in ﬁbroblasts
from CLN5-deﬁcient patients [125].
A recent study reported that CLN5 is essential for the recruitment of
retromer, which is responsible for the sorting and recycling of lysosomal
receptors [126]. In this article, the authors showed that in HeLa cells
overexpressing HA-tagged CLN5 and myc-tagged sortilin, a lysosomal
enzyme transporter, both proteins coimmunoprecipitate. Once they
knock down the CLN5 gene by RNA interference, they show that the sta-
bility of sortilin and Cation-Independent Mannose 6-Phosphate Recep-
tor (CIMPR) diminishes, but they also show that mature cathepsin D
levels do increase, which is not inconsistent since alternative lysosomal
targeting pathways exist for cathepsin D [127]. This study also claims
that defects in the recruitment of the retromer is responsible for the
loss of the function of the CIMPR transporter. Such function for CLN5
is inconsistent with its properties as a soluble lysosomal protein. Also
a very modest reduction in the retromer subunits VPS35 and VPS26 is
presented [126]. Moreover, the obtained results also contradict to a pre-
vious study. Seamanused siRNA to knock downVPS26 inHeLa cells, and
reported increased expression of CIMPR [128]. In the same report, using
a pulse-chase experiment it was conﬁrmed that there is no increased
turnover of the CIMPR in the VPS26 knock-down cells [128].
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theless, the high relative expression level of CLN5 in CNS neurons and
microglial cells [117,118] as well as the defective myelination in the
brain of Cln5-/- mice and late infantile CLN5 disease patients [118] indi-
cate the particular importance of CLN5 function in the brain. Loss of
CLN5 function can lead to selective neurodegeneration in multiple
ways: it may directly affect neuronal viability, it could cause abnormal
microglial activation leading to neurotoxicity, and ﬁnally it deﬁnitely
causes dysfunction of oligodendrocytes resulting in hypomyelination
that can disrupt axonal signal propagation leading to synapse loss and
eventually axonal and neuronal degeneration.
2.6. CLN6
Up-to-date there is little understanding of how mutations of the
CLN6 gene cause late infantile CLN6 disease [129]. CLN6 is a transmem-
brane Endoplasmic Reticulum (ER) protein without any posttransla-
tional modiﬁcations reported to date in its 311 amino acids (27 kDa)
and without any known function or homologous proteins in NCBI,
Ensembl or other protein databases [130,131]. Northern blot analysis
in different human and murine tissues has revealed that the CLN6/
Cln6 transcripts are ubiquitously present in different tissues [132].
Cln6 expression is developmentally regulated in murine brain with
greatest expression in the cerebellum and hypothalamus. From a cellu-
lar perspective, from P14 onward in mice, Cln6mRNA expression is the
highest in cells of cortical layers II-VI, Purkinje cells in the cerebellum,
and the dentate gyrus and CA1 region in the hippocampus [133].
CLN6 has been associated with autophagy, regulation of pH and en-
docytosis [134–136]. Thelen et al. claimed that they found age-
dependent increases in the autophagosomal marker, LC3-II, in the
brain of Cln6 mutant (nclf) mice as compared to wild type mice by
Western blot [134]. The obtained results are not conclusive in our opin-
ion, as they show very slight differences in the densitometric band anal-
ysis of LC3-II expression and show no differences as compared to LC3-I
bands, that correspond to the protein not associated to autophago-
somes. The tubulin bands seem to be overexposed, so the shown ratio
of LC3-II to tubulin seems not reliable for comparisons [134]. The au-
thors also claim that p62 protein, known to recognize toxic cellular
waste to be processed by autophagy, is accumulated in the brain of
nclf mice, but there is an issue with the amount of protein loaded and
it is difﬁcult to ascertain differences between nclf and wild type mice
[134].
Mutant CLN6 leads to the common phenotype in NCL cells such as ac-
cumulation of autoﬂuorescent lipopigments, subunit c of mitochondrial
ATP synthase, free cholesterol and phospho- and glycosphingolipids in
lysosome-derived storagebodies [134,136–140]. It is remarkable, though,
that CLN6 is known to be retained in the Endoplasmic Reticulum (ER)
with no colocalization with lysosomal markers and also neither the
synthesis, sorting nor theproteolytic processing of the lysosomal enzyme,
cathepsin D is affected in ﬁbroblasts from patients with CLN6 disease, in
sheep (OCL6) and mouse (nclf) models [141]. However, arylsulfatase A,
responsible for the lysosomal hydrolysis of sulfatides, was strongly re-
duced in all of the mutant CLN6 cell lines compared with controls [141].
Nevertheless, Lobel and colleagues have shown that there are no differ-
ences in the total mannose 6-phosphate proteome of brain material
between CLN6 disease patients and healthy controls [142].
Recently, a new role for CLN6 in biometalmetabolismwas proposed.
Aberrant biometalmetabolismhas been studied in other neurodegener-
ative disorders such as Alzheimer's and Parkinson's diseases [143]. The
accumulation of zinc, copper, manganese and cobalt has been shown
in CLN6mutantMerino and South Hampshire sheep at the age of symp-
tom onset [144]. A recent report by Kanninen et al. [145] also demon-
strated the accumulation of these biometals in the spinal cord, cortex,
heart and liver of Cln6 mutant (nclf) mice. At 12 weeks of age, the
most pronounced alterations in the levels of bothCln6 transcript and tis-
sue biometals were observed in the spinal cord and heart, whereas at24weeks of age, both Cln6 transcript and biometal changeswere detect-
ed in the cerebellum and heart. At this age it is also remarkable that an
inverse relationship between regional Cln6mRNA expression and accu-
mulation of biometals was found [145]. Accumulation of these 4
biometals and sustained reduction in Cln6 mRNA in the mice hearts
was evident by 32 weeks of age. Biometal disregulation seems to result
as CLN6 failure as the accumulation occurs speciﬁcally when signiﬁcant
loss of Cln6 transcript is detected in each respective tissue. In the same
study [145] the authors related the loss of proper CLN6 function and
the accumulation of zinc to Zip7 expression, a zinc/manganese trans-
porter that they found overly expressed in cerebellar Purkinje cells of
Cln6mutant (nclf) mice. Their data though do not support this hypoth-
esis as the ratio of zinc in nclf compared to control brain fractions does
not correlate with the expression of Zip7 in the same cell subfractions
[145]. In a later report from the same group, Grubman et al. claim that
CLN6 colocalizes with Zip7 in primarymouse cortical neurons using an-
tibodies against the respective endogenous proteins coupled to second-
ary antibodies detected by ﬂuorescence confocal microscopy [146].
However, the results show very unspeciﬁc binding of both markers
and no reliable colocalization results should be derived from the pre-
sented photos. Also, in this report the authors claim again that zinc ac-
cumulates in subcellular fractions that display Zip7 loss in the occipital
lobe of presymptomatic CLN6 mutant sheep. The displayed results,
consisting of the analysis of zinc contents in control and CLN6 mutant
subfractions, however, do not correlate with the shown expression of
Zip7 [146].
In conclusion, further research efforts are needed to clarify the pre-
cise function of CLN6. Nevertheless, the selective neurodegeneration
in CLN6 deﬁciency could be easily linked to the observed accumulation
of biometals, especially to zinc. Zinc is a key modulator of intracellular
and intercellular neuronal signaling, and zinc dyshomeostasis can
cause neuronal cell death [147]
2.7. CLN7
CLN7 disease, a variant late infantile phenotype, is caused by defects
in the MFSD8 gene. Analysis of RNA expression by Northern blot in a
Turkish family that harbored differentMFSD8mutations showed ubiq-
uitous MFSD8 expression at very low levels with higher amounts in
heart, liver and pancreas [148]. Analyses of rat neuronal, astroglial and
microglial cultures using real-time RT–PCR showed thatMfsd8 mRNA
was 12 and 6.4 times more abundant in neurons than in astrocytes
and microglial cells, respectively [149]. The same study showed that
ratMfsd8 transcripts were 2.4 and 5 times more abundant in the hippo-
campus than in the cortex and midbrain, respectively [149].
MFSD8 is a multispanning integral lysosomal membrane protein.
Not too much is known about it apart from being a member of the
major facilitator superfamily (MFS) of secondary active permeases,
which are proteins that transport small substrates (inorganic and or-
ganic cations, sugars and sugar phosphates, drugs, neurotransmitters,
and amino acids) across membranes [150]. The substrates of MFSD8,
its mode of transport, and physiological function, however, are un-
known. Several biochemical studies have shown colocalization of
MFSD8 (CLN7) with different lysosomal markers [148,149,151–153].
Sharifﬁ et al. showed colocalization of endogenously expressed CLN7
and LAMP1 in mouse hippocampal neurons [149]. Siintola et al. proved
colocalization of HA-taggedwild type andmutant CLN7with LAMP-1 in
transiently transfected COS-1 cells [148]. More recently, Steenhuis et al.
showed colocalization of lysotracker red and LAMP1 with over-
expressed GFP-tagged CLN7 in HeLa cells [153]. None of the expressed
pathogenic mutations identiﬁed in patients with CLN7 disease altered
the protein trafﬁcking and lysosomal localization [148,149,154]. Upon
arrival in lysosomes, CLN7 is cleaved twice by lysosomal cysteine prote-
ases releasing N- and C-terminal fragments [154].
In conclusion, future research has to identify the transported
substrate(s) of CLN7 and if CLN7 has a neuron-speciﬁc function, which
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2.8. CLN8
The CLN8 gene is mutated in two distinct clinical NCL phenotypes:
the progressive epilepsy with mental retardation (EPMR) also known
as Northern Epilepsy, a juvenile-onset phenotypic variant, and a more
severe late-infantile NCL variant [155]. A naturally-occurring Cln8mu-
tant, mnd (motor neuron degeneration) mouse model exhibiting a dis-
ease phenotype similar to that of late-infantile CLN8 disease patients
[155–157] has been used to study the disease. Several studies using
analysis of human autopsy or mouse tissues have concluded that RNA
transcripts of the CLN8/Cln8 gene are ubiquitously expressed but are
highest in the human heart, liver, pancreas and kidney, and within the
mouse brain, cortex and hippocampus are predominant locations
[155,158].
CLN8 is an ER-resident transmembrane protein of predicted 286
amino acid (aa) residues that contains 5 hydrophobic regions including
a TLC (TRAM-LAG1-CLN8) domain, and recycles between ER and ER-
Golgi intermediate compartment (ERGIC) using an ER-retrieval signal
(KKRP) in its cytoplasmic C-terminus in nonneuronal cells [155,157,
159].
CLN8 mutations do not affect the protein localization at the ER
but CLN8 has also been located outside the ER in a specialized
subcompartment of the polarized epithelial Caco-2 cells [160], in the
Golgi, endosomes and lipid rafts of mouse ﬁbroblasts [161], in light
membrane fraction different from ER after fractionation of mouse
brain [160] as well as in the proximity of plasma membrane in hippo-
campal neurons [160,162].
The 200 aa (62–262 aa) TLC (TRAM-LAG1-CLN8) domain of CLN8 has
been proposed to play a role in ceramide synthesis and glycosphingolipid
trafﬁcking, and also in catalyzing the synthesis of ceramide-like moieties
and/or stimulate lipid synthesis [159]. In spite of being unknown, the
function of CLN8 has been tightly related to lipid homeostasis [125,
163–168]. Recently an induction of CLN8 mRNA expression was found
in a model of chemically induced Gaucher disease, a sphingolipid degra-
dation disorder caused by the deﬁciency of lysosomal β-glucosidase
[168]. In the same study, the level of CLN8mRNA was further increased
in the presence of Lyso-GL1, a potent bioactive lipid substrate of acid β-
glucosidase. The study by Zhang et al. also indicated that in cells derived
from Gaucher disease patients, there was an increased basal expression
of CLN8 mRNA relative to control cells [168]. Another study linked cer-
amide levels and their synthesis to CLN8 activity. Haddad et al. found
that mnd mouse-derived ﬁbroblasts presented a decreased generation
of ceramide measured by mass spectrometry in comparison to normal
controls [125]. More importantly, the levels of ceramide were increased
when CLN8 was overexpressed in human ﬁbroblasts [125]. Prior studies
by Hermansson et al. in brains from EPMR patients are in accordance
with the results obtained by Haddad and colleagues, as the lipidomic
analysis of the samples showed reduced levels of ceramide, galactosyl-
and lactosylceramide and sulfatide as well as a decrease in long fatty
acyl chain-containing molecular species within the sphingolipids [165].
Another study by Kuronen et al. used mass spectrometric analysis to re-
veal reduced levels of galactolipids in cerebral cortical tissue from mnd
mice, which correlated with the subsequent diminished myelin matura-
tion [164].
Other studies have pointed to other possible functions for CLN8 such
as in oxidative and ER stresses, mitochondrial function, calciumhomeo-
stasis, inﬂammation and apoptosis [167,169–172]. Overexpression of
wild type, but not mutant, CLN8 has also been found to induce cell pro-
liferation and protection against NMDA-induced apoptosis in human
neuroblastoma cell lines [162].
All in all, further studies are needed to determine the exact role of
CLN8 in lipid homeostasis to better understand the link between CLN8
deﬁciency and neurodegeneration. Lipid homeostasis is particularlyimportant for the CNS, as this organ has a high concentration of lipids,
second only to adipose tissue, and it has been shown that lipid deﬁcits
in the brain cause dendritic spine degeneration, synapse loss, neuroin-
ﬂammation, and eventual neurodegeneration [173].
2.9. CLN9
The scarce reports about CLN9 have erroneously attributed CLN5 dis-
ease to CLN9 phenotype [124,174]. CLN9 disease was ﬁrst described to
have a similar clinical presentation as CLN3 disease [174]. Fibroblasts
from CLN9-deﬁcient patients were characterized by rounded cell bodies
and prominent nucleoli, poor cell attachment, increased cell proliferation
rate and increased sensitivity to etoposide-induced apoptosis [174]. The
authors also suggested that the CLN9 gene might have an impact on
sphingolipid metabolism as they showed that the activity of the key en-
zyme of the ceramide de novo synthesis pathway, serine palmitoyl trans-
ferase, is increased by more than 100% but also observed a strong
decrease of ceramide and sphingomyelin and the glycosphingolipids
lactosylceramide, ceramide trihexoside, and globoside levels in CLN9-
deﬁcient ﬁbroblasts [174]. Nevertheless, a novel mutation in the CLN5
gene (p.Gln232X) was lately identiﬁed as causative for the wrongly as-
sumed CLN9 variant andWestern blotting proved the presence of a trun-
cated CLN5 protein in patient ﬁbroblasts [125].
2.10. CLN10 (cathepsin D)
CLN10 disease is an autosomal recessive congenital disorder caused
by mutations in the Cathepsin D gene encoding the lysosomal enzyme
cathepsin D (CTSD) [29,175]. It is characterized as congenital NCL and
survival is a matter of hours or days but juvenile onset forms of CLN10
disease have also been reported in the literature [175].
The CTSD protein is ubiquitously expressed in most mammalian tis-
sues whereas in the retina it is mostly expressed in the pigment epitheli-
um, ganglion cells, and Müller cells [176]. CTSD is a lysosomal enzyme
belonging to the pepsin family of proteases and is one of the most
studied aspartic proteases [177]. Human CTSD is synthesized and
translocated into the Endoplasmic Reticulum (ER) as an inactive precur-
sor proenzyme (53 kDa), processed into a proteolytically active, interme-
diate proenzyme (48 kDa), and ﬁnally transported through the
endosomes into the lysosomes [178,179]. The mature form of human
CTSD is composed of two polypeptides interlinked by disulphide bridges
[180]. Aspartic acid residues contained on both polypeptides are essential
for the enzymatic activity of the protein [177,180]. The consequences of
CTSD mutation on the expression, proteolytic activity or cell processing
of the enzyme in the development of CLN10 disease have been largely
discussed. In the ﬁrst reported clinical case of juvenile CLN10 disease var-
iant, two missense mutations in the CTSD gene (p.Phe229Ile and
p.Trp383Cys)were found that caused reduced proteolytic activity and di-
minished amount of CTSD in patient ﬁbroblasts [175] but activitywas not
completely abrogated as in the congenital case, and this fact might have
been key in determining a less severe clinical phenotype. In the same
study it was found that in mouse 3T3 cells transfected with either
humanwild type or p.Phe229Ile mutant CTSD, human andmouse endog-
enous CTSD colocalize. However, when 3T3 cells were transfected with
human p.Trp383Cys mutant CTSD, only a small amount of the mutant
human protein colocalized with mouse CTSD, whereas most of
p.Trp383Cys CTSDwas detected in non-lysosomal compartments, in par-
ticular within the ER [175]. In a patient of Pakistani originwith congenital
CLN10 disease, immunohistochemistry of brain sections revealed the ab-
sence of the CTSD protein but when this mutated CTSD was transiently
expressed in BHK cells, a truncated form of CTSD was produced and ap-
peared stable, butwas enzymatically inactive [29]. Fritchie et al. published
a study on ﬁbroblasts from another congenital CLN10 disease patient har-
boring amutation in exon 3 of the Cathepsin D gene (p.Ser100Phe), show-
ing that cathepsin D activity was marginal, but the protein appeared
stable and normally processed [181].
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two cell processes that are extensively discussed in this review regarding
most of the NCL types. CTSD is considered as a central player in the apo-
ptotic response, but its importance is cell type dependent [193]. For in-
stance, CTSD mediates cytochrome c release and caspase activation
during staurosporine-induced apoptosis in human ﬁbroblasts [187].
CTSD is a major component of lysosomes and functions as a highly active
endopeptidase with an optimum pH between 3.0 and 5.0, playing an ob-
vious role in the degradation and turnover of cellular components under
nutrient-deﬁcient conditions [177]. Several studies have reported dys-
functions in macroautophagy in CTSD deﬁciency, showing accumulation
of autophagosomes [190] or accumulation of autoﬂuorescent storagema-
terial and increased levels of LC3-II [194] in neurons of CTSD-deﬁcient
mice. These two major functions of CTSD in apoptosis and
macroautophagy are closely related as it has been shown that lucanthone,
an autophagic inhibitor drug induces apoptosis via CTSD accumulation in
different breast cancer cells [192]. CTSD is supposed to have activity at
physiologic pH and it has been suggested to promote apoptosis upon its
translocation to the cytosol [195–197].
In conclusion, the strong involvement of CTSD in autophagy and ap-
optosis, two processes heavily utilized during brain development [198,
199], can explain the extremely short disease course of congenital
CLN10 disease.
2.11. CLN11 (progranulin)
The ﬁrst report of homozygous mutations in the progranulin gene
(PGRN) in two siblings suffering from a newly described type of adult
onset neuronal ceroid lipofuscinosis was published in 2012 [200].
Progranulin gene expression was detected in epithelial cells, bone mar-
row, spleen, lymph nodes, and cells of the innate immune system [201,
202]. In the CNS, gene expression and protein analysis have revealed
that progranulin is mainly expressed in neuroinﬂammatory microglia
andneocortical neurons, pyramidal and granule cells of the hippocampus,
cerebellar Purkinje cells, in the ventromedial hypothalamus, and inmotor
neurons [202–205]. Progranulin is a 68.5-kDa secretory protein that
works as a growth factor. It is a multidomain protein linked by six di-
sulphide bridges that is proteolytically cleaved in the linking regions by
matrix (MMP) and disintegrin metalloproteases (ADAM), and neutrophil
secreted serine proteases to generate individual 6-kDa cleavage products
that are called granulins A-G [206–209]. Progranulin is involved inmulti-
ple physiological processes and distinct pathologies, such as tumorigene-
sis, inﬂammation, autoimmune disorders and neurodegenerative
diseases [206,208–214]. Along with lipofuscin accumulation reduced
synaptic connectivity and plasticity, altered ubiquitination and myelin
formation have been found in the brain of progranulin-deﬁcient mice
[200,210,215].
Progranulin has been suggested to play a role in lysosomes.
Progranulin could be transported into lysosomes by sortilin receptor
[216] as it binds to this protein. Sortilin has been shown to be an alterna-
tive to CIMPR into lysosomal sorting [217]. Also, granulins cleaved from
progranulin bind to CpG oligodeoxynucleotides at lysosomes in macro-
phages, enabling Toll-like receptor 9 signaling [218]. Furthermore, in
progranulin-deﬁcient mice, accumulation of the autophagy-related re-
ceptor, p62 and the lysosomal protease cathepsin D was increased in
the cerebral cortex, and p62 and LAMP1 were found to be accumulated
in the ventral posteromedial nucleus/ventral posterolateral nucleus of
thalamus [215,219]. A recent study by Tanaka et al. examining traumatic
brain injury in progranulin-deﬁcientmice suggests that progranulin has a
central role in preventing lysosomal dysfunction [220]. Using confocalmi-
croscopy it was demonstrated that after traumatic brain injury in wild
type mice LAMP1 and progranulin colocalize in activated microglia of
the cerebral cortex [220]. Most importantly, it was also shown that the
production of progranulin is increased in activated microglia after trau-
matic brain injury, and that progranulin deﬁciency leads to decreased
mammalian target of rapamycin complex 1 (mTORC1) activity with aresultant increase of lysosomal biogenesis in activated microglia and ex-
acerbated neuronal damage in the cerebral cortex [220]. mTORC1 nega-
tively regulates transcription factor EB (TFEB), which is a master
regulator of lysosomal genes and its nuclear translocation induces lyso-
somal biogenesis [221,222].
All in all, the role of progranulin in autophagy and lysosomal homeo-
stasis, especially in microglial cells, seems to be relevant to the neuro-
pathological changes in CLN11 disease. Further studies are needed,
however, to determine how exactly progranulin deﬁciency leads to
selective, late-onset neurodegeneration.
2.12. CLN12
Mutations in the ATP13A2 (CLN12) gene are a known cause of Kufor-
Rakeb syndrome, a rare form of autosomal recessive juvenile or early-
onset, levodopa-responsive Parkinsonism with dementia [223,224].
Kufor-Rakeb syndrome-affected individuals show not only typical NCL
symptoms but also extrapyramidal involvement. A recent study using
postmortem pathological analysis in a Kufor-Rakeb syndrome patient
with a homozygous missense mutation in the ATP13A2 gene conﬁrmed
extensive lipofuscin deposits in the cortex, basal nuclei, cerebellum, and
retina [224]. Several studies have also linked a single base deletion in
the ATP13A2 gene to NCL in Tibetan Terriers [225,226].
CLN12 (ATP13A2) mRNA transcripts are ubiquitously expressed in
most human tissues, with particularly high levels in the brain, and
also but to a lesser extent in skeletal muscle and in kidney. Within the
brain, the highest expression is in the ventral midbrain containing
substantia nigra [223].
The CLN12 (ATP13A2) gene, also known as KRPPD, PARK9, HSA9947,
RP-37C10.4, encodes a lysosomal transmembrane protein of 36 kDa con-
taining 10 predicted transmembrane domains [223,227,228]. Several
homozygous and compound heterozygous mutations are known to re-
sult in truncation of the ATP13A2 protein leading to a loss of function
[229–231].
ATP13A2 belongs to the family of P-Type ATPases as a type 5. P-Type
ATPases use the energy derived from ATP hydrolysis to shuttle various
substrates, ranging from cations and heavy metals to lipids, across
biological membranes against their concentration gradients (reviewed
in [232]). Wild type ATP13A2 is known to be targeted to acidic compart-
ments, such as the late endosomes and lysosomes, as showed by co-
localization with LAMP1/2a and lysotracker [223,233]. Recent studies in
Kufor-Rakeb syndrome patient-derived ﬁbroblasts and ATP13A2-
deﬁcient cell lines have shown that the loss of the protein increases the
size and number of lysosomes and dramatically perturbs lysosomal func-
tion by impairing pHhomeostasis, lysosomal enzymeproteolytic process-
ing, lysosomal degradation and lysosome-mediated clearance of
autophagosomes [223,234,235]. Lately, in both differentiated SH-
SY5Y cells and rat primary neurons, the endogenous ATP13A2
was shown to localize to multi-vesicular bodies, a late endosomal
compartment that also plays a key role in the autophagic pathway
[236].
It has also been observed that loss of ATP13A2 function impairs oxida-
tive stress response in human neuroblastoma cells [233] and human
ATP13A2 expression is upregulated under this cell event [237]. Further-
more, patient-derived ATP13A2-deﬁcient olfactory neurospheres show
increased sensitivity toward Zn2+ toxicity [238]. Defective autophagy
and accumulation of defective proteinsmight account for the observed al-
terations in oxidative stress response.
ATP13A2 has also been shown to protect against α-synuclein toxicity
in several model systems including yeast, C. elegans andmammalian cells
[239].α-Synuclein is a small presynaptic protein linked to Parkinson dis-
ease. ATP13A2 could protect againstα-synuclein toxicity by anyof the fol-
lowing mechanisms: enhancing lysosomal degradation of protein
aggregates [234,235,240], regulating the autophagic delivery of the pro-
tein into lysosomes [234,235], promoting the removal of the protein
from the cell via exosomes reducing the α-synuclein stress [236] or by
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toxicity [241,242].
Other proposed functions for ATP132, recently reviewed by Van Veen
et al. [243], are linked to its role as a cation transporter and involvement in
the regulation of Mn2+, Zn2+, Mg2+, and H+ homeostasis. Also, a role as
ﬂipase in lipid transport across membranes is proposed due to its close
phylogenetic relation to the type 4 P-Type ATPases [243].
In conclusion, the protection by ATP13A2 againstα-synuclein toxicity
is the strongest functional link to Parkinsonism in CLN12 disease. More-
over, since normal neuronal function depends on tightly regulated
Mg2+ and Zn2+ homeostasis, Mg2+ voltage-dependently blocks
NMDA-type glutamate receptors [244] and Zn2+ is a key modulator
of intracellular and intercellular neuronal signaling [147], loss of
the cation transporter function of ATP13A2 can cause dysregulated
neurotransmission and eventually dementia characteristic for CLN12
disease.
2.13. CLN13 (cathepsin F)
Mutations in the Cathepsin F (CTSF, CLN13) gene were originally de-
scribed in mice. Cathepsin F-deﬁcient mice develop neurological disease
beginning at 12–16 months of age with lack of coordination, weakness
and premature death. They also display excess accumulation of
autoﬂuorescent granules in the cerebral cortex, hypothalamus, cerebellar
Purkinje cells and anterior horn cells of the spinal cord, and cortical atro-
phy and glial activation [245]. Lately, rare mutations in CTSF, after geno-
mic analysis by linkage mapping followed by exome sequencing, have
been described in 3 families with adult-onset NCL with predominant de-
mentia and motor disturbances, rather than epilepsy [246].
Immunohistochemical analysis has determined that cathepsin F is
strongly expressed in neuronal cells, mainly in the cerebral cortex, cer-
ebellum and hippocampus, and in hepatocytes and Leydig cells in testis
[247]. Cathepsin F is a cysteine protease consisting of 484 amino acids
and contains a 251 amino acid propeptide encoding an N-terminal
cystatin-like proregion that can work as a cysteine protease inhibitor
[248–251]. Cathepsin F is tagged with mannose 6-phosphate residues
in the cis-Golgi network and targeted to the lysosomes by the CIMPR
transporter [252].
Besides its role as a lysosomal enzyme, cathepsin F has been recently
associated to proteasomedegradation and autophagy. Confocalmicrosco-
py in HEK 293T cells overexpressing either wild type or N-terminally
truncated forms of cathepsin F revealed that mutants accumulated in
perinuclear aggresome-like inclusions, and were conﬁrmed as p62-
positive aggregates [253]. The p62 protein recognizes toxic cellular
waste to be processed by autophagy. Interestingly, Jeri et al. suggested a
compensatory role of autophagy as the evaluated mutants colocalized in
a much more deﬁned pattern with the autophagy marker, microtubule-
associated protein 1A/1B-light chain 3 (LC3B) [253]. The same study
also found that the truncated forms of cathepsin F caused a 2–3 fold
increase in caspase activation [253].
Other functions of cathepsin F have been linked to MHC class II
maturation and peptide loading in antigen-presenting cells [254], and
lipoprotein degradation [255].
All in all, it is completely unclear how mutations of cathepsin F cause
adult-onset NCL with predominant dementia and motor disturbances.
However, the slow development of the disease indicates that either the
function of cathepsin F ismildly affected or the loss of its function is partly
compensated, and long time is needed until the accumulated damages,
due to lysosomal/autophagic defects, reaches a threshold and the disease
symptoms appear.
2.14. CLN14 (Potassium channel tetramerization domain-containing
protein 7)
Potassium channel tetramerization domain-containing protein 7
(KCTD7) has been extensively linked to progressive myoclonic epilepsy[256,257] and also to ataxia [258]. A missense homozygousmutation of
KCTD7 was recently found to cause a NCL subtype in a Mexican family
affected by infantile-onset progressive myoclonic epilepsy, vision loss,
cognitive and motor regression, premature death, and prominent
NCL-type storage material [259].
KCTD7 is a highly conserved protein consisting of 289 amino acids,
and in mouse it is mainly expressed in the brain and more speciﬁcally
in cortical neurons, in granular and pyramidal cell layers of the hippo-
campus, and in cerebellar Purkinje cells [259,260]. When GFP-tagged
KCTD7 was expressed in a Cln3 mutant cerebellar cell line it showed
broad, somewhat punctate cytoplasmic localization and distinct signal
at the plasma membrane [259]. The studies by Kousi et al. in BHK cells
transfected with HA-tagged wild type and mutant KCTD7 indicated
that KCTD7 is a soluble cytosolic protein [261].
KCTD7 is a member of the KCTD protein family [262]. This family of
proteins shares an N-terminal BTB/POZ domain that shows sequence
homology to the T1 tetramerization domain found in voltage-gated po-
tassium channels [262]. The structure and organ localization of KCTD7
suggests that it is involved in hyperpolarization of the cell membrane
via interaction with a component of the ubiquitin ligase complex. In
fact, overexpression of KCTD7 in murine neurons hyperpolarizes the
cell membrane and decreases the excitability of transfected neurons in
patch clamp experiments [260].
KCTD7 has been shown to directly interact with Cullin-3, a compo-
nent of E3 ubiquitin-protein ligases that selectively tag proteins for deg-
radation by the proteasome [260]. Staropoli et al. determined that the
KCTD7 mutation originally described for CLN14 disease by them,
which is not in the N-terminal BTB/POZ domain, abolished the interac-
tion of KCTD7with Cullin-3 [259]. They suggested that the abolished in-
teraction between KCTD7 and Cullin-7 could be tilting the balance of
degradation versus accumulation of substrate proteins towards the sec-
ond event, and that could in turn elicit a toxic response within the cell
[259].
In conclusion, KCTD7, as a regulator of K+ conductance in neurons,
clearly affects neuronal excitability [260] providing a direct link to pro-
gressive myoclonic epilepsy in CLN14 disease. Further studies are need-
ed, however, to determine if the membrane potential-affecting role of
KCTD7 is speciﬁc to glutamatergic or GABAergic neurons, or restricted
to certain neuronal subtypes.
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